TEZSPIRE Demonstrates Positive Phase 3 Results for Eosinophilic Esophagitis

AstraZeneca and Amgen announced positive top-line results from the Phase 3 CROSSING trial for TEZSPIRE (tezepelumab-ekko) in eosinophilic esophagitis (EoE). The drug showed statistically significant and clinically meaningful improvements in histologic remission and dysphagia frequency/severity at week 24, sustained through week 52. These findings suggest a potential new treatment option for EoE patients, addressing a significant unmet medical need.